StockNews.AI
CAPR
StockNews.AI
3 days

CAPR Investors Have the Opportunity to Lead the Capricor Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

1. Capricor faces a federal securities class action for alleged misleading statements. 2. A Complete Response Letter from the FDA led to a significant stock price drop. 3. Investors with losses over $50,000 are encouraged to participate in the class action. 4. The BLA for deramiocel was denied by the FDA requiring further clinical data. 5. Deadline for lead plaintiff status is September 15, 2025.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The FDA's denial of Capricor's BLA negatively impacted investor confidence and stock price.

How important is it?

The securities litigation signifies serious allegations affecting investor sentiment and stock price.

Why Short Term?

The immediate financial implications due to class actions will likely pressure stock in the near term.

Related Companies

AAPLTSLAMSFT
If You Suffered Losses Exceeding $50,000 in Capricor between October 9, 2024 and July 10, 2025 Securities Litigation Partner James (Josh) Wilson Encourages you to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here to find out if you qualify for the class action] NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) and reminds investors of the September 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that defendants provided investors with material information concerning Capricor’s lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA, specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application. Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.   Faruqi & Faruqi, LLP also encourages anyone with information regarding Capricor’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. Learn whether you may be eligible to participate in the Capricor Therapeutics class action by visiting http://www.faruqilaw.com/CAPR or contacting Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3a3fa937-87cb-45e3-b706-966046064eee

Related News